Adicet Bio Inc ACET

Healthcare Biotechnology

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

NDAQ:ACET - Post by User

Adicet Bio Inc

<< Previous

Bullboard Posts

Next >>

(3)
•••

Post by yllanycropon Aug 16, 2020 3:16pm

265 Views

Post# 31415097

really now

this has gone from $20 in 2018 to $2.31 now.
I'm an old guy and would like to invest but if it's been too good to be true for years. why now??? any info would be appreciated
glta

<< Previous

Bullboard Posts

Next >>

NEO Battery Materials: Making companies like Rheinmetall and Mercedes-Benz less dependent on China's battery market